![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Clearance for Alere Reader Platform and Alere BinaxNOW Influenza A & B Card 2
FDA Grants Clearance for Alere Reader Platform and Alere BinaxNOW Influenza A & B Card 2
![Green_Light.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/Green_Light.gif?t=1625610540&width=430)
Massachusetts–based Alere has won FDA marketing clearance for its Alere Reader, a diagnostic analyzer that can be used in point-of-care and laboratory settings.
The device will be initially available for use with the BinaxNOW Influenza A & B Card 2, with other lateral flow applications and assays to follow. The reformulated test card has achieved Class II designation under the new FDA reclassification requirements.
The Alere Reader is a further extension of the company’s flu portfolio.
The device also received in-vitro diagnostic CE marking in August 2016. — Cynthia Jessup
Upcoming Events
-
21Oct